open access

Vol 83, No 12 (2012)
ARTICLES
Get Citation

Prognostic factors in patients with primary invasive vaginal carcinoma

Paweł Blecharz, Marian Reinfuss, Jerzy Jakubowicz, Piotr Skotnicki, Wojciech Wysocki, Kazimierz Karolewski, Krzysztof Urbański
Ginekol Pol 2012;83(12).

open access

Vol 83, No 12 (2012)
ARTICLES

Abstract

Aim of the study: Aim of the study was the assessment of prognostic factors in the group of primary invasive vaginal carcinoma (PIVC) patients subjected to radical radiation therapy. Material and methods: The analysis was performed for the group of 152 PIVC patients treated with intracavitary brachytherapy alone (16.5%), the combination of brachytherapy and external radiotherapy (78.9%), or external radiotherapy alone (4.6%). The relationship was investigated between treatment outcome and the following demographic, clinical and histopathological features: age, duration of pathological symptoms, number of births given, prior hysterectomy, haemoglobin level, Karnofsky performance status score, primary tumour location in vagina, length of vagina involved, FIGO stage, gross appearance, histological type, and tumour grade. Results: Five-year disease-free survival was observed in 46.1% of the patients (70/152). Patients below 60 years of age, with Karnofsky score of 80-90, diagnosed with PIVC in stage I0 or II0, and with tumour of grade G1 or G2 had significantly higher 5-year disease-free survival. Multifactoral analysis showed that age below 60 and FIGO stage I0 and II0 are independent favourable prognostic factors. Conclusions: The independent prognostic factors in PIVC patients treated with radical radiotherapy are patient age and FIGO stage.

Abstract

Aim of the study: Aim of the study was the assessment of prognostic factors in the group of primary invasive vaginal carcinoma (PIVC) patients subjected to radical radiation therapy. Material and methods: The analysis was performed for the group of 152 PIVC patients treated with intracavitary brachytherapy alone (16.5%), the combination of brachytherapy and external radiotherapy (78.9%), or external radiotherapy alone (4.6%). The relationship was investigated between treatment outcome and the following demographic, clinical and histopathological features: age, duration of pathological symptoms, number of births given, prior hysterectomy, haemoglobin level, Karnofsky performance status score, primary tumour location in vagina, length of vagina involved, FIGO stage, gross appearance, histological type, and tumour grade. Results: Five-year disease-free survival was observed in 46.1% of the patients (70/152). Patients below 60 years of age, with Karnofsky score of 80-90, diagnosed with PIVC in stage I0 or II0, and with tumour of grade G1 or G2 had significantly higher 5-year disease-free survival. Multifactoral analysis showed that age below 60 and FIGO stage I0 and II0 are independent favourable prognostic factors. Conclusions: The independent prognostic factors in PIVC patients treated with radical radiotherapy are patient age and FIGO stage.
Get Citation

Keywords

Vaginal Cancer, radiotherapy, prognostic factors

About this article
Title

Prognostic factors in patients with primary invasive vaginal carcinoma

Journal

Ginekologia Polska

Issue

Vol 83, No 12 (2012)

Bibliographic record

Ginekol Pol 2012;83(12).

Keywords

Vaginal Cancer
radiotherapy
prognostic factors

Authors

Paweł Blecharz
Marian Reinfuss
Jerzy Jakubowicz
Piotr Skotnicki
Wojciech Wysocki
Kazimierz Karolewski
Krzysztof Urbański

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl